Payment overview · 2025
General Payments
$1,049.55
57 reported records · 22 companies
Healthcare provider profile · identity verified
Paula Rickard Bennett, MD
Allopathic & Osteopathic Physicians|Family Medicine · HONESDALE, PA · NPI 1245292556
Verified facts
What the public records show
CMS Open Payments records show Paula Rickard Bennett, MD received $1,049.55 in general payments during 2025 across 57 reported records.
ABBVIE INC. accounted for 19.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 293 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $201.43 | 19.2% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $97.47 | 9.3% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $92.27 | 8.8% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $91.82 | 8.8% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $78.33 | 7.5% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $64.05 | 6.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.55 | 4.7% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $40.77 | 3.9% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $40.44 | 3.9% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $35.47 | 3.4% | 2 | 2025 |
| AERIN MEDICAL INC. | Unresolved — no canonical attribution shown | $29.83 | 2.8% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $28.37 | 2.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $28.09 | 2.7% | 2 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $23.89 | 2.3% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $23.44 | 2.2% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $22.51 | 2.1% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.66 | 2.1% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.77 | 1.8% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $16.55 | 1.6% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.31 | 1.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.95 | 1.4% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.58 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,049.55 | 57 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $161.03 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $79.86 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $79.86 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $79.17 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $78.33 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $54.96 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $54.96 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $54.96 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $45.67 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $42.63 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $40.77 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $40.44 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $37.31 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $37.31 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $35.47 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $31.39 | 3 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $30.89 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $30.11 | 2 | 2025 |
Source payment records
|
|||||
| RHINAER STYLUS Normalized: rhinaer stylus |
Device | AERIN MEDICAL INC. | $29.83 | 1 | 2025 |
Source payment records
|
|||||
| VIVAER STYLUS Normalized: vivaer stylus |
Device | AERIN MEDICAL INC. | $29.83 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $28.37 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $28.09 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $25.41 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $23.89 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $23.89 | 1 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc. | $23.44 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $22.51 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $22.51 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $21.66 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.05 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $18.77 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 293 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 50 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 70 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 185 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
88 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
50 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
90 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
185 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
293 | 55 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 830 | 158 |
| Metoprolol Succinate | Metoprolol Succinate | 728 | 146 |
| Losartan Potassium | Losartan Potassium | 633 | 144 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 599 | 140 |
| Atorvastatin Calcium | Atorvastatin Calcium | 460 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 436 | 105 |
| Lisinopril | Lisinopril | 385 | 87 |
| Hydrochlorothiazide | Hydrochlorothiazide | 335 | 81 |
| Simvastatin | Simvastatin | 330 | 70 |
| Metformin Hcl Er | Metformin Hcl | 328 | 69 |
| Furosemide | Furosemide | 310 | 71 |
| Omeprazole | Omeprazole | 308 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 306 | 65 |
| Gabapentin | Gabapentin | 302 | 63 |
| Eliquis | Apixaban | 293 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 227 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 219 | 43 |
| Warfarin Sodium | Warfarin Sodium | 196 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 187 | 32 |
| Montelukast Sodium | Montelukast Sodium | 185 | 37 |
| Ozempic | Semaglutide | 185 | 28 |
| Clonazepam | Clonazepam | 175 | 32 |
| Sertraline Hcl | Sertraline Hcl | 173 | 33 |
| Metformin Hcl | Metformin Hcl | 172 | 42 |
| Allopurinol | Allopurinol | 171 | 34 |
| Potassium Chloride | Potassium Chloride | 170 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 162 | 33 |
| Buspirone Hcl | Buspirone Hcl | 145 | 29 |
| Mirtazapine | Mirtazapine | 142 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 141 | 29 |
| Baclofen | Baclofen | 136 | 31 |
| Alprazolam | Alprazolam | 135 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 120 | 33 |
| Atenolol | Atenolol | 117 | 28 |
| Valsartan | Valsartan | 117 | 25 |
| Tramadol Hcl | Tramadol Hcl | 116 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 109 | 28 |
| Trazodone Hcl | Trazodone Hcl | 103 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 48 |
| Alendronate Sodium | Alendronate Sodium | 99 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 99 | 23 |
| Glipizide Er | Glipizide | 98 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 97 | 18 |
| Famotidine | Famotidine | 96 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 96 | 25 |
| Carvedilol | Carvedilol | 93 | 21 |
| Trulicity | Dulaglutide | 90 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 30 |
| Synthroid | Levothyroxine Sodium | 88 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 86 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 85 | 17 |
| Lorazepam | Lorazepam | 78 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 13 |
| Meloxicam | Meloxicam | 76 | 17 |
| Finasteride | Finasteride | 74 | 21 |
| Raloxifene Hcl | Raloxifene Hcl | 74 | 18 |
| Enalapril Maleate | Enalapril Maleate | 72 | 19 |
| Ibuprofen | Ibuprofen | 72 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 72 | 18 |
| Xarelto | Rivaroxaban | 72 | 12 |
| Jardiance | Empagliflozin | 70 | 15 |
| Prednisone | Prednisone | 69 | 24 |
| Sucralfate | Sucralfate | 69 | 12 |
| Donepezil Hcl | Donepezil Hcl | 67 | 18 |
| Temazepam | Temazepam | 66 | suppressed |
| Ezetimibe | Ezetimibe | 65 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 62 | 18 |
| Bupropion Xl | Bupropion Hcl | 58 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 56 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 54 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 53 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 53 | suppressed |
| Levetiracetam | Levetiracetam | 53 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 12 |
| Amoxicillin | Amoxicillin | 52 | 31 |
| Propranolol Hcl Er | Propranolol Hcl | 52 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 51 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 51 | 15 |
| Farxiga | Dapagliflozin Propanediol | 50 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | suppressed |
| Irbesartan | Irbesartan | 46 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 46 | suppressed |
| Memantine Hcl | Memantine Hcl | 45 | suppressed |
| Vascepa | Icosapent Ethyl | 44 | suppressed |
| Azithromycin | Azithromycin | 43 | 34 |
| Clotrimazole | Clotrimazole | 43 | 17 |
| Januvia | Sitagliptin Phosphate | 43 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 42 | 12 |
| Spironolactone | Spironolactone | 42 | 12 |
| Meclizine Hcl | Meclizine Hcl | 40 | 17 |
| Methylprednisolone | Methylprednisolone | 40 | 33 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 36 |
| Digoxin | Digoxin | 39 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 25 |
| Doxepin Hcl | Doxepin Hcl | 38 | suppressed |
| Carisoprodol | Carisoprodol | 36 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Celecoxib | Celecoxib | 35 | suppressed |
| Fluconazole | Fluconazole | 35 | 22 |
| Invokana | Canagliflozin | 34 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 33 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 33 | suppressed |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 11 |
| Nystatin | Nystatin | 32 | 24 |
| Tradjenta | Linagliptin | 32 | suppressed |
| Estradiol | Estradiol | 31 | 11 |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | suppressed |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Cephalexin | Cephalexin | 29 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 26 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 26 | 18 |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 18 |
| Ziprasidone Hcl | Ziprasidone Hcl | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | 11 |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 12 |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Felodipine Er | Felodipine | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 13 |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 14 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Dapsone | Dapsone | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Oxazepam | Oxazepam | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,049.55 · 57 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AREXVY, AUSTEDO XR, BEXSERO, BREZTRI, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FANAPT, FARXIGA, FREESTYLE LIBRE 3, Flexitouch Plus, JARDIANCE, Kerendia, LEQEMBI, MOUNJARO, NEXLETOL, NURTEC ODT, Nimbl, ONPATTRO, OPSUMIT, Ozempic, PREVNAR 20, PROLIA, QULIPTA, RHINAER STYLUS, Rybelsus, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, Tymlos, UBRELVY, ULTOMIRIS, UPTRAVI, VIVAER STYLUS, VRAYLAR, Wegovy, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error